Source:http://linkedlifedata.com/resource/pubmed/id/18949395
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2008-10-24
|
pubmed:abstractText |
Interaction of MUC1 with beta-catenin plays a significant role in tumor progression and invasion. However, the clinical significance of coexpression of MUC1 and subcellular beta-catenin expression in colorectal carcinoma remains unclear. The present study evaluated the clinicopathological significance of their combined expression for predicting prognosis. Seventy-seven colorectal carcinomas were subjected to immunohistochemical staining with anti-MUC1 KL-6 mucin and anti-beta-catenin monoclonal antibody. Positive KL-6 mucin expression was correlated with decreased membranous beta-catenin expression (P=0.022), while no correlation was found between positive KL-6 expression and nuclear beta-catenin expression (P=0.142). Preservation of membranous beta-catenin expression was detected in 35 cases (45.5%) and decreased membranous beta-catenin expression was found in 42 cases (54.5%). Negative KL-6 expression was detected in 31 cases (41.3%) and positive expression was seen in 46 cases (59.7%). Combined positive KL-6 expression and decreased membranous beta-catenin expression was found in 30 patients (39.0%), whose survival was significantly worse than that of patients with other expression patterns for these two molecules (53.3 vs. 84.4%, P=0.005). Multivariate analysis showed that this combination was as an independent predictor of survival. We concluded that the combined pattern of positive KL-6 expression and decreased membranous beta-catenin expression by colorectal carcinoma is a useful biomarker for distinguishing a subgroup of patients with a worse prognosis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1021-335X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1013-9
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:18949395-Adenocarcinoma,
pubmed-meshheading:18949395-Cell Membrane,
pubmed-meshheading:18949395-Colorectal Neoplasms,
pubmed-meshheading:18949395-Female,
pubmed-meshheading:18949395-Gene Expression,
pubmed-meshheading:18949395-Humans,
pubmed-meshheading:18949395-Immunohistochemistry,
pubmed-meshheading:18949395-Kaplan-Meier Estimate,
pubmed-meshheading:18949395-Male,
pubmed-meshheading:18949395-Mucin-1,
pubmed-meshheading:18949395-Prognosis,
pubmed-meshheading:18949395-Tumor Markers, Biological,
pubmed-meshheading:18949395-beta Catenin
|
pubmed:year |
2008
|
pubmed:articleTitle |
Positive KL-6 mucin expression combined with decreased membranous beta-catenin expression indicates worse prognosis in colorectal carcinoma.
|
pubmed:affiliation |
Minimally Invasive Surgery Center, Changzheng Hospital, Second Military Medical University, Shanghai, P.R. China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|